The underlying letter count in phase 2 with RAP patients excluded was 4.4. With further tweaking of baseline characteristics in phase 3, this letter count should be regarded as the minimum target if the upcoming study replicates the efficacy of the previous. In addition, control outperformed by approximately .6 letters in phase 2.
Add to My Watchlist
What is My Watchlist?